Annelyn Torres-Reverón (Annelyn Torres-Reveron)

Years Active: 2018-2022
Publications (10 Years): 6

DHR Health Institute for Reseach and Development

State University of New York, Health Sciences Center (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

DHR Health Institute for Reseach and Development Oct 28 2019

United States

Clinical research Scientist

University of Texas Rio Grande Valley Edinburg Sep 01 2016 - Oct 21 2019

United States

Assistant Professor :: Biomedical Sciences, School of Medicine

Education History

State University of New York, Health Sciences Center

United States

PHD

Publications

Haissam S Elzaim, Kristina P Vatcheva, Annelyn Torres-Reverón, Gregery Pequeno, Monica M Betancourt-Garcia
Comparative analysis of all-terrain vehicles, motorcycle and automobile-related trauma in a rural border community of the USA. BMJ open 12 (9) (2022)
Joshua E Pagán-Busigó, Jonathan López-Carrasquillo, Caroline B Appleyard, Annelyn Torres-Reverón
Beyond depression and anxiety; a systematic review about the role of corticotropin-releasing hormone antagonists in diseases of the pelvic and abdominal organs. PloS one 17 (3) (2022)
Michael Serra-Torres, Raul Barreda, David Weaver, Annelyn Torres-Reverón
Delayed Presentation of Patients with Hip Fractures during the COVID-19 "Stay-at-Home" Order in the Southmost Region of the United States. Advances in orthopedics 2021 (2021)
Kevin Mutore, Jiyun Lim, Demba Fofana, Annelyn Torres-Reverón, Jeffrey J Skubic
Hearing hoofbeats? Think head and neck trauma: a 10-year NTDB analysis of equestrian-related trauma in the USA. Trauma surgery & acute care open 6 (1) (2021)
Annelyn Torres-Reverón, Maahrose Rana, Varesh Gorabi, Leslie L Rivera-Lopez, Caroline B Appleyard
Short treatment with antalarmin alters adrenal gland receptors in the rat model of endometriosis. PloS one 15 (1) (2020)
Annelyn Torres-Reverón, Leslie L Rivera-Lopez, Idhaliz Flores, Caroline B Appleyard
Antagonizing the corticotropin releasing hormone receptor 1 with antalarmin reduces the progression of endometriosis. PloS one 13 (11) (2018)

Annelyn Torres-Reverón.css-eqlu8i{font-size:small;padding-left:4px;} (Annelyn Torres-Reveron)